SGLT2 inhibitors: How a diabetes drug class evolves into the HF realm
Despite current established therapy, heart failure (HF) remains a leading cause of morbidity and mortality worldwide. Patients with HF had a substantially reduced median survival rate, regardless of age groups, compared with the general population.
